Incidence of and risk factors associated with nedaplatin-related hypersensitivity reactions
Authors:
- 25 January 2017
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 22 (3) , 593-599
Abstract
Nedaplatin (NDP)-related hypersensitivity reactions (HSRs) trigger adverse clinical events. Prediction and prevention of NDP-HSRs are thus essential to minimize the risk and maximize the benefit of NDP therapy. However, the incidence of NDP-HSRs and the associated risk factors remain unclear. We retrospectively examined patients who received NDP monotherapy between April 2011 and July 2015 in Nagoya University Hospital. HSRs severity was defined according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE ver.4). Risk factors for NDP-HSRs were determined using multivariate logistic regression. Of 111 patients who received NDP monotherapy, 90 (81%) were female; median age was 59 years (range, 29–78 years). Eighty-eight patients had gynecological cancer and 20 suffered from head and neck cancer. Eight of 111 patients (7.2%) experienced NDP-HSRs, six of which developed in the second NDP cycle. However, all patients with NDP-HSRs were treated with carboplatin (CBDCA) for more than three cycles. Grade 3 and 4 HSRs developed in 2 patients. NDP-HSRs were significantly associated with a history of CBDCA-HSRs (odds ratio 37.5, 95% confidence interval 5.38–262, p < 0.001) and with the interval between NDP administration and the previous platinum treatment (odds ratio 13.9, 95% confidence interval 1.23–158, p = 0.034). The risk of NDP-HSRs increases in patients with a history of CBDCA-HSRs and in those administered NDP for more than 6 months after previous platinum treatment. Such individuals must be closely monitored if given NDP, even if they are expected to benefit from the treatment.Keywords
This publication has 24 references indexed in Scilit:
- Platinum hypersensitivity and desensitizationJapanese Journal of Clinical Oncology, 2015
- Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization ProtocolClinical Therapeutics, 2015
- Comparison of nedaplatin-based versus cisplatin-based chemotherapy for advanced non-small cell lung cancer among East Asian populations: A meta-analysisScientific Reports, 2015
- Nedaplatin- versus cisplatin-based chemotherapy in the survival time of patients with non-small cell lung cancerMolecular and Clinical Oncology, 2015
- Carboplatin‐induced severe hypersensitivity reaction: Role of IgE‐dependent basophil activation and FcεRICancer Science, 2014
- Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065)Oncology Reports, 2012
- Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic ReviewMetal-Based Drugs, 2010
- Hypersensitivity to Oxaliplatin: An Investigation of Incidence and Risk Factors, and Literature ReviewOncology, 2009
- Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' HospitalGynecologic Oncology, 2007
- Analysis of Patients with Epithelial Ovarian Cancer or Fallopian Tube Carcinoma Retreated with Cisplatin after the Development of a Carboplatin AllergyGynecologic Oncology, 2002